Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bamlanivimab as monotherapy for high-risk COVID-19 patients with mild to moderate symptoms

Fivelstad et al., International Journal of Scientific Research, 11:7
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -144% Improvement Relative Risk Hospitalization 63% Bamlanivimab/e..  Fivelstad et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 483 patients in the USA Lower hospitalization with bamlanivimab/etesevimab (p=0.00059) c19early.org Fivelstad et al., Int. J. Scientific R.., Jul 2022 Favorsbamlanivimab/e.. Favorscontrol 0 0.5 1 1.5 2+
21st treatment shown to reduce risk in May 2021
 
*, now with p = 0.00036 from 21 studies, recognized in 7 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 335 outpatients with mild to moderate COVID-19 and at least one high-risk comorbidity, showing significantly lower hospitalization with bamlanivimab treatment compared to the control group.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron1-5.
risk of death, 144.2% higher, RR 2.44, p = 1.00, treatment 1 of 335 (0.3%), control 0 of 148 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 62.9% lower, RR 0.37, p < 0.001, treatment 21 of 335 (6.3%), control 25 of 148 (16.9%), NNT 9.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fivelstad et al., 31 Jul 2022, retrospective, USA, peer-reviewed, 6 authors.
This PaperBamlaniv../e..All
Abstract: ORIGINAL RESEARCH PAPER Volume - 11 | Issue - 07 | July - 2022 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH BAMLANIVIMAB AS MONOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS WITH MILD TO MODERATE SYMPTOMS Emergency Medicine MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, Kathryn Fivelstad STE 203 Las Vegas, NV 89107 USA. Tuong Pham Kristen Meacham Alberto Hazan Patrick Olivieri Michael Doctor * MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MS, Touro University Nevada. 874 American Pacic Drive #8801, Henderson, NV 89014. USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA *Corresponding Author ABSTRACT INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to progress from mild to severe disease, especially in patients with high-risk comorbidities. Monoclonal antibody treatment of COVID-19 with bamlanivimab has been proposed to decrease illness severity. Non-industry sponsored data is lacking. This study will investigate the effects of bamlanivimab on hospitalization and mortality when administered to patients with COVID-19. METHODS: This was a retrospective analysis of bamlanivimab use within eight emergency departments in Las Vegas, NV. Patients who tested positive for COVID-19 and met inclusion criteria for bamlanivimab but were not administered this treatment were used as a control group. Patients were tracked for hospital admissions and mortality for the 28 days following their treatment. RESULTS: 335 patients diagnosed with COVID-19 were treated with bamlanivimab infusion and tracked for hospitalization within 28 days. Of these patients, 21 (6.3%) required admission, including one who expired on day 46 after a prolonged ICU stay. Of the 148 control patients, 25 required admission (16.9%) and there were no deaths. Relative risk of hospitalization with administration of bamlanivimab was 0.37 (CI 95% 0.22 to 0.61, p<0.01). The absolute risk reduction is 10.6% making the number needed to treat for potential benet 9.4 (95% CI 6.0 to 19.9). CONCLUSION: The results of our study are in alignment with those of the clinical trials funded by Eli Lilly supporting bamlanivimab to reduce 28-day hospitalization for COVID-19 positive patients with mild to moderate symptoms and signicant comorbidities. KEYWORDS COVID-19; Bamlanivimab; Coronavirus; Monoclonal Antibody
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit